The Immunology and Cancer Program (Program 3) has been an integral component of the UCCRC for more than 20 years. It has 19 members from 5 departments, and is supported by a total of $7,660,269 in peer-reviewed funding (annual direct costs), with $2,154,936 from the NCI. Over the past grant period, program members have produced a total of 387 peer-reviewed publications, including 11% that were intraprogrammatic and 15% that were interprogrammatic collaborations. It is well established that tumors can express antigens that can be recognized by specific T cells or antibodies. Established immunologic therapies in the clinic include allogeneic bone marrow or blood stem cell transplantation, the monoclonal antibodies Herceptin and Rituxan, and the cytokines IL-2 and IFN-cc. However, as fundamental knowledge of the immune system continues to increase at a rapid pace, the potential for improving upon existing immune-based therapies, as well as for developing new immunotherapeutic approaches, continues to expand. The overall goals of the Immunology and Cancer Program are to foster the best possible research that has relevance for the cancer setting, to support an environment that brings new immunology concepts into preclinical models of anti-tumor immunity, and to translate fundamental discoveries into clinical application. A major accomplishment of the Program is the expansion of the clinical/translational component. These goals are supported by severa key Core Facilities, in particular the Flow Cytometry, Fitch Monoclonal Antibody, Immunohistochemistry, and the Human Immunologic Monitoring Cores. The Immunology and Cancer Program also depends on the services of the cGMP Facility (a UCCRC developing core) for preparation of clinical-grade immunotherapeutic products for clinical administration. By incorporating detailed scientific endpoint monitoring into clinical studies, new key information is being generated that has led to the development of new hypotheses that can then be interrogated back in the basic laboratory. Thus, the Immunology and Cancer Program has evolved into a clear example of bi-directional translational research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-N)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Sharifi, Marina N; Mowers, Erin E; Drake, Lauren E et al. (2016) Autophagy Promotes Focal Adhesion Disassembly and Cell Motility of Metastatic Tumor Cells through the Direct Interaction of Paxillin with LC3. Cell Rep 15:1660-72
Drazer, Michael W; Stadler, Walter M (2016) The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J 22:330-333
Epel, Boris; Redler, Gage; Pelizzari, Charles et al. (2016) Approaching Oxygen-Guided Intensity-Modulated Radiation Therapy. Adv Exp Med Biol 876:185-93
Sweis, Randy F; Medved, Milica; Towey, Shannon et al. (2016) Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer :
Volden, Paul A; Skor, Maxwell N; Johnson, Marianna B et al. (2016) Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation. Cancer Prev Res (Phila) 9:367-78
Stein, Michelle M; Hrusch, Cara L; Gozdz, Justyna et al. (2016) Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med 375:411-21
Baron, Beverly W; Baron, Rebecca M; Baron, Joseph M (2016) The Relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6 in Benign and Malignant Human Lymphoid Tissues. Biochem Biophys Rep 6:1-8
King, Andrea C; Hasin, Deborah; O'Connor, Sean J et al. (2016) A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder. Biol Psychiatry 79:489-98
Appelbe, Oliver K; Zhang, Qingbei; Pelizzari, Charles A et al. (2016) Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment. Mol Pharm 13:3457-3467
Morrison, Gladys; Lenkala, Divya; LaCroix, Bonnie et al. (2016) Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget 7:38359-38366

Showing the most recent 10 out of 534 publications